Baxdrostat bioavailability and bioequivalence study

Trial Identifier:	CIN-107-112
Sponsor:	AstraZeneca
NCTID::	NCT05963009
Start Date:	March 2020
Primary Completion Date:	April 2020
Study Completion Date:	April 2020
Condition:	Hypertension

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
United States, Ohio	Cincinnati, Ohio, United States, 45227

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.